Vitespen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vitespen
Accession Number
DB06400
Description
Not Available
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Endoplasmin (human tumor rejection antigen 1)
  • Heat shock protein-peptide complex-96 vaccine
  • Vitespen
External IDs
  • HSPPC 96
  • HSPPC-96

Pharmacology

Indication

Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

HSPPC-96 is a protein peptide complex consisting of a 96 kDa heat shock protein (Hsp), gp96, and an array of gp96-associated cellular peptides. Immunisation with HSPPC-96 induces T-cell specific immunity against these peptides; gp96 is not immunogenic per se. The non-covalent binding of gp96 to peptides is neither selective nor restricted to cell types. Thus, the collection of gp96-associated peptides represents the antigenic peptide pool of a cell; this is the basis of the peptide-specific immunogenicity elicited by HSPPC-96.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Vitespen can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Vitespen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Vitespen can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Vitespen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Vitespen can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Vitespen can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Vitespen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
H3598Y1TLJ
CAS number
492448-75-6

References

General References
  1. Minev BR: Technology evaluation: HSPPC-96, antigenics. Curr Opin Mol Ther. 2003 Dec;5(6):680-7. [PubMed:14755896]
  2. Caudill MM, Li Z: HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther. 2001 May;1(3):539-47. [PubMed:11727524]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMelanoma, Malignant1
3CompletedTreatmentRenal Cell Adenocarcinoma1
3TerminatedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentGliosarcoma / Recurrent Adult Brain Tumor / Recurrent Glioblastoma1
2CompletedNot AvailableLung Cancers / Non-Small Cell Lung Carcinoma (NSCLC) / Pulmonary Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentFollicular Lymphoma (FL) / Small Lymphocytic Lymphoma1
2CompletedTreatmentSarcomas1
2RecruitingTreatmentGlioblastomas1
2RecruitingTreatmentGlioma of Brain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on March 19, 2008 10:29 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates